比亚迪(01211.HK)参与投资基金并签署合夥协议 投资人工智能及大数据
比亚迪(01211.HK)公布,与凯利易方、梅州紫辰、黄晓明、翁伟芳、宋荣琴、孔剑平、易建军、赵旦、袁雨辰签署《广东易方畅达股权投资合夥企业(有限合夥)合夥协议》。易方畅达以合夥方式组建,投资方式包括权益投资及其他符合法律,法规规定的投资。
投资范围主要为人工智能及大数据相关的软、硬件行业企业。该基金总规模为3.21亿元人民币。公司作为该基金的有限合夥人认缴出资5,000万元。
公司指,参与投资基金有利於获得人工智能及大数据相关的软、硬件行业的产业投资资源,享受行业发展红利,获得长期投资回报。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.